Close
What would you like to look for?
Site search
Search filters

ASTRA Therapeutics Seed Round Closing

22 December 2025

ASTRA Therapeutics SA, a start-up company developing precision drugs against eukaryotic pathogens, announced the successful closing of its CHF 7.75m seed financing round.

The investment was co-led by MIG Capital and Digitalis...

GlycoEra AG closes Series-B-financing round

30 May 2025

GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, announced the closing of an oversubscribed USD 130m Series-B-financing.

EraCal Therapeutics AG to license certain assets to Novo Nordisk

31 January 2024

EraCal Therapeutics AG ("EraCal"), a Swiss biotech start-up company focusing on the fight of obesity has licensed certain assets to Novo Nordisk for a total amount of EUR 235m in a collaboration and license deal.

GlycoEra AG increases its Series A Financing Round with investment by BMS

22 January 2024

GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS).

Luciole Medical AG acquires Spiegelberg Group

3 July 2023

Luciole Medical, a Swiss medical technology company specialized in brain monitoring, acquires Spiegelberg GmbH & Co. KG (Spiegelberg), an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.

Follow-On Offering of Oculis Holding AG

8 June 2023

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share, for gross proceeds of USD 40.25m, before deducting underwriting discounts and commissions and offering expenses.

ImmunOs Therapeutics AG to raise CHF 74m Series B financing

7 June 2022

ImmunOs Therapeutics AG has agreed to a CHF 74 million Series B financing led by incoming co-lead investors Samsara Biocapital, Lightspeed Venture Partners and Gimv, corner-stoned by GL Capital, Mission BioCapital, Peak 6 Strategic Capital and Fiscus Financial

Dubai's DP World and Swissterminal enter strategic partnership

27 January 2020

DP World and Swissterminal, the leading container terminal operator in Switzerland, have entered a strategic partnership. DP World will take a stake of 44% in Swissterminal Holding AG with the Mayer family, the business' founder,...

Sale of the BASF Schweiz AG site in Klybeck / Basel

31 July 2019
11 July 2019

BASF Schweiz AG has sold its approximately 120,000 sqm stake in the Klybeck site in Basel to Swiss Life.

Dr. Thomas Gelzer and Dr. Francesca Pesenti were responsible for notarization and execution of this transaction.

Riemser invests in Anwerina

29 February 2012

RIEMSER Arzneimittel AG invests in anwerina AG, a life science company specialized in the development and marketing of innovative orthopedic pharmaceutical and medical products.

VISCHER advises anwerina AG in the transaction. The...